William T. Abraham et al. JCHF 2018;j.jchf

Slides:

Advertisements

Similar presentations

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.

Advertisements

SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Randomized Trial to Assess Catheter Ablation Versus.

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Assessing the Risk of Progression From Asymptomatic.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Limitations of Ejection Fraction for Prediction.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiopoietic Stem Cell Therapy in Heart Failure:

Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Mitral Valve Interventions in the Real.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Tolerability and efficacy of carvedilol in patients.

From: Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis.

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,

Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;

Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.

by Peter J. Schwartz, Maria Teresa La Rovere, Gaetano M

Chronic Heart Failure CHF

Equipoise ”Balance of forces or interests”

Figure 8 Implanted devices for the management of heart failure

Erratum Heart Rhythm Volume 8, Issue 4, (April 2011)

Propensity Scores: Uses and Limitations

Figure 7 European Society of Cardiology 2016

INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.

Study Design Patients with LBBB and LV dysfunction

Shadi Al Halabi et al. JACEP 2015;1:

Nat. Rev. Cardiol. doi: /nrcardio

G. Michael Felker et al. JCHF 2014;2:

Sexual Activity and Chronic Heart Failure

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106

Nat. Rev. Cardiol. doi: /nrcardio

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Incremental predictive value of CR after repetitive squatting exercise and FC from cardiopulmonary testing exercise results over clinical (red) and echocardiographic.

Anaerobic threshold responder analysis

The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months. The effect of GOODCOLL versus POORCOLL on LVEF, LVEDV and scar at 4 months.

Wayne L. Miller et al. JCHF 2013;1:

Nikole J. Byrne et al. BTS 2017;j.jacbts

Mohit K. Turagam et al. JACEP 2017;3:

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Svend A. Mortensen et al. JCHF 2014;2:

Heather M. Wilson et al. BTS 2018;3:

Connie W. Tsao et al. JCHF 2016;4:

Gordon R. Reeves et al. JCHF 2017;j.jchf

Peter E. Carson et al. JCHF 2015;3:

Bar chart of cardiac volumes and EF in the healthy individuals, HCM LVH− patients and HCM LVH+ patients. Blue bars show the indexed diastolic volumes (EDVI.

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Emilce Trucco et al. JACEP 2018;j.jacep

Romain Gallet et al. BTS 2016;1:14-28

Romain Gallet et al. BTS 2016;1:14-28

Rami Doukky et al. JCHF 2016;4:24-35

Maneesh Sud et al. JCHF 2017;5:

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.

Nikole J. Byrne et al. BTS 2017;j.jacbts

Simpson's biplane ejection fraction (A), and two-dimensional speckle-tracking global longitudinal strain (B) in patients receiving clozapine treatment,

Absolute mortality difference Change in LVEF from baseline

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Lifetime heart failure risk*

Satoru Kishi et al. JCHF 2014;2:

Khadijah Breathett et al. JCHF 2017;5:

Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.

Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.

Rick A. Nishimura et al. JACC 2017;70:

John P. Boehmer et al. JCHF 2017;5:

Time to first event analysis revealed a significant difference in estimated event-free (death or hospitalisation) survival between patients with left ventricular.

Gianluigi Savarese et al. JCHF 2016;4:

Fig. 3 Echocardiographic analyses of cardiac function.

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Change in 6 min walk distance at 12 months in subgroups defined by baseline characteristics. The mean (95% CI) for the difference between CABG and medical.

Constantijn Franssen et al. JCHF 2016;4:

Adjusted cumulative disability incidence by sex and heart failure status. Adjusted cumulative disability incidence by sex and heart failure status. The.

Presentation transcript:

William T. Abraham et al. JCHF 2018;j.jchf.2018.04.010 Efficacy Results by EF Groups CCM treatment effects (difference between control and CCM groups and 95% confidence intervals) for patients with ejection fraction (EF) <35% versus EF ≥35% for (A) Peak VO2, (B) Minnesota Living With Heart Failure questionnaire (MLWHFQ), (C) New York Heart Association (NYHA) functional class, and (D) 6-min hall walk test. CCM = cardiac contractility modulation; EF = ejection fraction. William T. Abraham et al. JCHF 2018;j.jchf.2018.04.010 2018 The Authors